Related Experiment Video
Updated: Feb 8, 2026

Burn Injury-Induced Pain and Depression-Like Behavior in Mice
Published on: September 29, 2021
A proteomic study of the pulmonary injury induced by microcystin-LR in mice
Sujuan Zhao1, Hong Sun2, Wei Yan3
1School of Public Health, Anhui Medical University, Hefei 230032, China.
Abstract:
MCLR has been shown to act as potent hepatotoxin, and recent studies showed that MCs can accumulate in lung tissue and exert adverse effects. However, the exact mechanism still remain unclear. The present study mainly focuses on the impairments of respiratory system after MCLR exposure in mice. After intratracheal instillation with MCLR (0, 10 and 25 μg/kg bw), histological change was examined in MCLR exposure groups. Results indicated that exposure of MCLR led to serious histopathology alteration and apoptosis in lung of mice. To further our understanding of the toxic effects of MCLR on the lung, we employed a proteomic method to search the mechanisms behind MCLR-induced pulmonary injury. In total, 38 proteins were identified to be significantly altered after MCLR exposure. These proteins involved in inflammatory response, apoptosis, cytoskeleton, and energetic metabolism, suggesting MCLR exerts complex toxic effects contributing to pulmonary injury. Furthermore, MCLR also induced pulmonary inflammation, as manifested by up-regulating the protein levels of interleukin-1β (IL-1β) and p65 subunit. Our results indicated that MCLR exerts lung injury mainly by generating inflammation and apoptosis.
Insights
Microcystin-LR (MCLR) causes lung injury in mice by inducing inflammation and apoptosis. This study identified 38 altered proteins, revealing complex toxic effects contributing to pulmonary damage.
Area of Science:
- Environmental toxicology
- Pulmonary pathology
- Proteomics
Background:
- Microcystin-LR (MCLR) is a known hepatotoxin.
- Emerging evidence suggests MCLR accumulation in lung tissue causes adverse effects.
- The precise mechanisms of MCLR-induced lung injury remain unclear.
Purpose of the Study:
- To investigate the respiratory system impairments following MCLR exposure in mice.
- To elucidate the molecular mechanisms underlying MCLR-induced pulmonary injury.
Main Methods:
- Intratracheal instillation of MCLR in mice at varying doses (0, 10, 25 μg/kg bw).
- Histopathological examination of lung tissues.
- Proteomic analysis to identify altered proteins.
- Quantification of inflammatory markers like IL-1β and p65.
Main Results:
- MCLR exposure caused significant histopathological alterations and apoptosis in mouse lungs.
- Proteomic analysis identified 38 significantly altered proteins involved in inflammation, apoptosis, cytoskeleton, and metabolism.
- MCLR exposure led to pulmonary inflammation, evidenced by increased levels of IL-1β and p65.
Conclusions:
- MCLR induces significant lung injury in mice.
- The primary mechanisms involve the generation of inflammation and apoptosis.
- Proteomic insights reveal complex toxic effects contributing to pulmonary damage.
Related Concept Videos
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

